Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
申请人:Kirin Pharma Kabushiki Kaisha
公开号:EP2088141A2
公开(公告)日:2009-08-12
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein X = CH or N; Z = O or S; L = O or S; M = CR10R11, wherein R10 and E11 = H, alkyl, or alkoxy, NR12 wherein R12 = H or alkyl; R1, R2, and R3 = H or optionally substituted alkoxy; R4 = H; R5-8 = H, halogen, alkoxy or the like; and R9 = alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T = O, S, or NH; R14 = an optionally substituted carbocyclic or heterocyclic ring; and R15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 = H, optionally substituted alkyl, or an optionally substituted carbocyclic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.
本发明的目的是提供具有强效抗肿瘤活性的化合物。本发明的化合物由式(I)或其药学上可接受的盐或溶液表示:
其中 X = CH 或 N;Z = O 或 S;L = O 或 S;M = CR10R11,其中 R10 和 E11 = H、烷基或烷氧基,NR12,其中 R12 = H 或烷基;R1、R2 和 R3 = H 或任选取代的烷氧基;R4 = H;R5-8 = H、卤素、烷氧基或类似物;R9 = 任选被 -R14、-T-R15 或 -NR16R17 取代的烷基,其中 T = O、S 或 NH;R14 = 任选取代的碳环或杂环;以及 R15-17 = 烷基或任选取代的碳环或杂环,或 -NR18R19 其中 R18 和 R19 = H、任选取代的烷基或任选取代的碳环或杂环,或任选取代的碳环或杂环。